NASDAQ:KPTI Karyopharm Therapeutics (KPTI) Stock Price, News & Analysis $0.34 -0.09 (-20.45%) As of 03:23 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Karyopharm Therapeutics Stock (NASDAQ:KPTI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get KPTI alerts:Sign Up Key Stats Today's Range$0.34▼$0.4350-Day Range$0.43▼$2.1252-Week Range$0.34▼$10.99Volume1.41 million shsAverage Volume1.06 million shsMarket Capitalization$7.71 millionP/E RatioN/ADividend YieldN/APrice Target$11.50Consensus RatingModerate Buy Company Overview Karyopharm Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on discovering and developing medicines that target nuclear transport proteins involved in cancer and other serious diseases. The company’s technology platform centers on selective inhibitors of nuclear export, particularly exportin 1 (XPO1), a protein that helps regulate the movement of key molecules between a cell’s nucleus and cytoplasm. Karyopharm’s primary product is XPOVIO (selinexor), an oral XPO1 inhibitor. In the United States, XPOVIO is used in combination regimens for certain adults with relapsed or refractory multiple myeloma and relapsed or refractory diffuse large B-cell lymphoma. The company has also evaluated selinexor in additional hematologic and solid-tumor cancers and continues to develop other investigational compounds based on its nuclear export platform. Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm serves patients through commercial and development activities in the United States and international markets, supported by regulatory approvals and partnerships in selected regions. Its work is primarily focused on oncology, with research aimed at expanding the use of XPO1 inhibition and developing potential treatments for diseases with limited therapeutic options.AI Generated. May Contain Errors. Read More Karyopharm Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreKPTI MarketRank™: 3.555935322725 of 5 starsKaryopharm Therapeutics scored higher than 71% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingKaryopharm Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 1 strong buy rating, 3 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialKaryopharm Therapeutics has a consensus price target of $11.50, representing about 3,068.0% upside from its current price of $0.36.Amount of Analyst CoverageKaryopharm Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Karyopharm Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Karyopharm Therapeutics are expected to grow in the coming year, from ($4.70) to ($2.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Karyopharm Therapeutics is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Karyopharm Therapeutics is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Karyopharm Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted27.16% of the float of Karyopharm Therapeutics has been sold short.Short Interest Ratio / Days to CoverKaryopharm Therapeutics has a short interest ratio ("days to cover") of 4.79.Change versus previous monthShort interest in Karyopharm Therapeutics has recently decreased by 23.00%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKaryopharm Therapeutics does not currently pay a dividend.Dividend GrowthKaryopharm Therapeutics does not have a long track record of dividend growth. News and Social Media3.0 / 5News SentimentN/A News SentimentKaryopharm Therapeutics has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Karyopharm Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for KPTI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Karyopharm Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $488.00 in company stock.Percentage Held by Insiders1.68% of the stock of Karyopharm Therapeutics is held by insiders.Percentage Held by Institutions66.44% of the stock of Karyopharm Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Karyopharm Therapeutics' insider trading history. Receive KPTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KPTI Stock News HeadlinesKaryopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)October 1, 2026 | prnewswire.comKaryopharm Therapeutics (KPTI) Stock Fair Value Falls After Split Analyst Views On Trial UpdatesSeptember 4, 2026 | finance.yahoo.comWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.October 14 at 1:00 AM | Awesomely (Ad)Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (IDYA), BioMarin Pharmaceutical (BMRN) and Karyopharm Therapeutics (KPTI)September 3, 2026 | theglobeandmail.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 1, 2026 | prnewswire.comKaryopharm Therapeutics Inc.: Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO (selinexor) Plus Ruxolitinib for Patients with MyelofibrosisAugust 31, 2026 | finanznachrichten.deKaryopharm Submits SNDA Seeking Accelerated Approval For XPOVIO In Combination With RuxolitinibAugust 31, 2026 | rttnews.comKaryopharm Submits SNDA For XPOVIO Plus Ruxolitinib In Myelofibrosis; Stock UpAugust 31, 2026 | rttnews.comSee More Headlines KPTI Stock Analysis - Frequently Asked Questions How have KPTI shares performed this year? Karyopharm Therapeutics' stock was trading at $7.36 at the beginning of 2026. Since then, KPTI stock has decreased by 95.1% and is now trading at $0.3630. How were Karyopharm Therapeutics' earnings last quarter? Karyopharm Therapeutics Inc. (NASDAQ:KPTI) issued its earnings results on Thursday, August, 13th. The company reported ($2.32) EPS for the quarter, missing the consensus estimate of ($1.37) by $0.95. The firm earned $33.43 million during the quarter, compared to the consensus estimate of $32.19 million. Read the conference call transcript. When did Karyopharm Therapeutics' stock split? Karyopharm Therapeutics's stock reverse split on the morning of Wednesday, February 26th 2025.The 1-15 reverse split was announced on Monday, February 24th 2025. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Karyopharm Therapeutics IPO? Karyopharm Therapeutics (KPTI) raised $102 million in an initial public offering on Wednesday, November 6th 2013. The company issued 6,800,000 shares at a price of $14.00-$16.00 per share. How do I buy shares of Karyopharm Therapeutics? Shares of KPTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Karyopharm Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Karyopharm Therapeutics investors own include NVIDIA (NVDA), Bristol Myers Squibb (BMY), Alibaba Group (BABA), Tesla (TSLA), Gilead Sciences (GILD), Advanced Micro Devices (AMD) and Pfizer (PFE). Company Calendar Last Earnings8/13/2026Today10/14/2026Next Earnings (Estimated)11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 KPTI's financial health is in the Red zone, according to TradeSmith. KPTI has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:KPTI CIK1503802 Webwww.karyopharm.com Phone(617) 658-0600FaxN/AEmployees228Year Founded2008Price Target and Rating Average Price Target for Karyopharm Therapeutics$11.50 High Price Target$28.00 Low Price Target$3.00 Potential Upside/Downside+3,282.4%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($13.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$196.04 million Net Margins-153.28% Pretax Margin-153.30% Return on EquityN/A Return on Assets-145.18% Debt Debt-to-Equity RatioN/A Current Ratio0.79 Quick Ratio0.76 Sales & Book Value Annual Sales$146.07 million Price / Sales0.05 Cash FlowN/A Price / Cash FlowN/A Book Value($16.00) per share Price / Book-0.02Miscellaneous Outstanding Shares22,680,000Free Float22,300,000Market Cap$7.71 million OptionableOptionable Beta1.04 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:KPTI) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersMicroscopic footage reveals immune cells destroying cancer cellsTime-lapse footage from a recent clinical study shows Natural Killer cells attacking and eliminating cancer ce...Market Tactic | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredElon pays this company. Every time.Every Tesla built since 2012 pays this small, overlooked supplier a fee for its technology. So does every Star...Behind the Markets | SponsoredElon will prove them wrong againElon Musk's critics said self-driving cars were a pipe dream. Today, Tesla robotaxis carry passengers with no ...Paradigm Press | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredDid you grab your copy yet?Bill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarte...Profits Run | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karyopharm Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
